Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Venous Thromboembolism (VTE) Clear all
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

NCT03521908
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 23, 2026, 2:22 PM EDT
Not yet recruiting No phase listed Observational

Duke Virtual IntEgrated Workflow

NCT07406074
View directory record Official record
Conditions
Falls Injury, Readmission Rates, CLABSI - Central Line Associated Bloodstream Infection, Catheter Associated Urinary Tract Infection, Hospital Acquired Pressure Injury, Venous Thromboembolism (VTE), Nurses, Satisfaction, Patient, Length of Stay
Interventions
Co-Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

NCT00077805
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Early Phase 1 Interventional Results available

Statin Use in Patients With Acute VTE

NCT02331095
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Atorvastatin, Anticoagulation Therapy
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Not listed No phase listed Observational

Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans

NCT00925808
View directory record Official record
Conditions
Cancer, Venous Thromboembolism
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Early Phase 1 Interventional

Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis

NCT02285738
View directory record Official record
Conditions
Solid Tumor, Cancer
Interventions
Aspirin, Simvastatin, Observation
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

OsciPulse Device for the Prevention of VTE

NCT04625673
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
Interventions
OsciPulse
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban, Enoxaparin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related

NCT06765681
View directory record Official record
Conditions
Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
Interventions
Diagnosis of both VTE and sepsis
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Withdrawn No phase listed Observational

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients

NCT01890044
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolus, Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

NCT00810784
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Educating Nurses About Venous Thromboembolism (VTE) Prevention

NCT02301793
View directory record Official record
Conditions
Venous Thromboembolism, Venous Thrombosis
Interventions
Nurse education in contemporary format, Nurse education in traditional format
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 23, 2026, 2:22 PM EDT